Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

Lara C. Pullen, PhD  |  November 11, 2019

A recent study advances the understanding of factors associated with a target serum urate level of 6 mg/dL or less. Researchers found such factors as having a rheumatologist as the main provider of gout care contributed to achieving and maintaining this outcome. However, the presence of co-morbidities lowered a patient’s chances for achieving the target serum urate level, even with allopurinol use…

How to Walk on Water & Climb Up Walls: 2019 ACR/ARP Annual Meeting gets an inspirational kickoff in Atlanta

Keri Losavio  |  November 9, 2019

ATLANTA—Did you know that Tasmanian wombats have cube-shaped poop or that no matter what size bladder someone has, they still pee in 20–30 seconds—even elephants? What do those factoids have to do with rheumatology? When keynote speaker David L. Hu, PhD, shared the information and how he discovered it, the stories incited laughter in the…

A Farewell Message from Outgoing Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP

Angus Worthing, MD, FACP, FACR  |  November 7, 2019

A farewell message from outgoing Government Affairs Committee Chair Angus Worthing urges ACR/ARP members to advocate for the rheumatology profession.

Making Rheumatologists’ Voices Count: A Conversation with Blair Solow, MD, Incoming Government Affairs Committee Chair

Vanessa Caceres  |  November 7, 2019

With multiple healthcare policy issues currently in play, Dr. Solow believes making rheumatologists’ voices heard is crucial to the specialty’s success.

Ellen M. Gravallese, MD, Begins ACR Presidency

Susan Bernstein  |  November 7, 2019

As Ellen M. Gravallese, MD, begins the ACR presidency, her goals include workforce expansion, improved access to care and support for members in all areas of practice.

New ARP President Janet Poole, PhD, OTR/L, FAOTA, Plans to Build Membership & Address Workforce Shortages

Carol Patton  |  November 6, 2019

Dr. Poole’s cited priorities include building an interprofessional membership team through developing resources and promoting rheumatology to health professionals in many disciplines.

2019 EULAR/ACR SLE Classification Criteria Offer Improved Sensitivity & Specificity

Susan Bernstein  |  November 6, 2019

The new EULAR/ACR classification criteria for SLE offer improved sensitivity and specificity, as well as more accurately reflect the current tests used to clinically diagnose SLE. A positive ANA test is obligatory…

Trump Nominates MD Anderson Oncologist as U.S. FDA Commissioner

Deena Beasley  |  November 4, 2019

(Reuters)—U.S. President Donald Trump has nominated Stephen Hahn, MD, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the U.S. Food and Drug Administration (FDA), the White House said on Friday. Dr. Hahn, a radiation oncologist who has been at MD Anderson in Houston since 2015, if confirmed would follow…

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2019

The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…

Insight into the Characteristics of Orphan Autoinflammatory Disorders

Carina Stanton  |  November 4, 2019

New research seeking to describe the characteristics of undefined, systemic autoinflammatory diseases may have identified distinct subgroups, including pericarditis and intellectual impairment…

  • « Previous Page
  • 1
  • …
  • 232
  • 233
  • 234
  • 235
  • 236
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences